Background: Irinotecan (CPT-11) is metabolized by esterase to form a SN-38, which is further conjugated by UGT1A1. Genetic polymorphism has been shown in a promoter region of UGT1A1 and is related to its activity. We investigated whether there might be an inter-individual difference in pharmacokinetics of SN-38 and its glucuronide, depending on the genotypes of UGT1A1.
Irinotecan (CPT-11), a novel anticancer agent used in the treatment of colon and lung cancers, is metabolized by esterase to form the active metabolite SN-38, which is further conjugated by UDP-glucuronosyltransferases (UGTs) to yield its glucuronide [1] . It appears that interindividual differences in pharmacokinetics of the SN-38 would cause variation in the effect of irinotecan. Recently Iyer et al. revealed that the UGT 1A1 isoform is responsible for the glucuronidation of SN-38 in vitro [1] .
The UGT1A1 conjugates bilirubin or several endogenous substrates. Decreased activity of the UGT1A1 is known to cause constitutional jaundice known as Crigler-Najjar syndrome and Gilbert's syndrome. Many mutated alleles of UGT1AJ leading to decreased enzyme activity have been noted in patients with these syndromes. The (TA) 6 TAA element normally exists within the promoter region of UGT1A1. However, UGT1A1*28 contains two extra nucleotides, TA, within the TATA box resulting in the sequence (TA) 7 TAA [2] . Monaghan et al. reported an association between the genotypes and bilirubin levels [3] . We postulated that UGT1A1*28 allele was one of the possible factors accounting for interindividual variations in drug conjugation by UGT1A1. The aim of this research was to determine whether there would be an inter-individual difference in pharmacokinetics of SN-38 and SN-38 glucuronide depending on the genotypes of UGT1A1.
Patients and methods
We examined the genotypes of UGT1A1 in nine male patients with lung cancer. The median age was 65 years (range 48-72 years). They were treated with irinotecan of 50 mg/m 2 by 1.5-hour infusion followed by carboplatin (300 mg/m 2 ) in hospitals affiliated with Nagoya University. The dose of irinotecan was determined by a prior dose-escalating study conducted by our group, in which dose-limiting toxicities including severe diarrhea were observed at a dose of 60 mg/m . Plasma samples were obtained at 1 5, 1.75, 2, 2.5, 3.5, 5.5, 9.5 and 25.5 hours after the beginning of irinotecan infusion. Plasma concentrations of irinotecan, SN-38 and SN-38 glucuronide were analyzed by high performance liquid chromatography. Area under the time versus concentration curve (AUC) was calculated using WinNonlin software. Genotypes of UGTIAI were determined by analyzing the sequence of 253-255-bp (-131 to +122) produced by polymerase chain reaction using genomic DNA prepared from the patients [4] . This research was approved by every Institutional Ethical Committee, and written informed consent was obtained from all patients.
Results
The genotyping analysis revealed one heterozygote (6/7) and one homozygote (7/7) for (TA) 7 TAA allele. The other seven patients were homozygote for (TA) 6 TAA allele (6/6, wild type). The bilirubin levels prior to chemotherapy were within normal range in all patients. Severe toxicity including hematological and diarrhea Figure 1 . Metabolic ratios (SN-38/SN-38 glucuronide) in patients with each genotypes of UGT1A1. There were each one patient with homozygote (7/7, triangle) and heterozygote (6/7, square) for (TA) 7 TAA allele (UGTIAI*28). Other seven patients were all homozygote (6/6, circle) for (TA) 6 TAA allele (mean ± standard deviation).
was not encountered in the patient with 7/7 genotype nor in some of the other patients.
However, metabolic ratios (SN-38/SN-38 glucuronide) in the patient with 7/7 genotype were higher than those in the patients with other genotypes (6/6 and 6/7, Figure 1 , Table 1 ). Further, of the patients examined in this study, the maximum concentration of SN-38 glucuronide was lowest in the one with 7/7 genotype. The patient with 6/7 genotype tended to have a higher metabolic ratio ( Figure 1 , Table 1 ). Biliary index proposed by Gupta et al. was more than 4000 only in the patient with 7/7 genotype [5] .
Discussion
Pharmacogenetics is the study of genetically determined alterations in a metabolic pathway of drug. Such alternations cause inter-individual variations in pharmacokinetics and, occasionally, drug response. For example, genetic polymorphism of thiopurine S-methyltransferase (TPMT) is extremely important in patients receiving 6-mercaptopurine (6-MP) in the treatment of leukemia. Given the standard doses of 6-MP, TPMT-deficient patients (incidence of one in 300) can not detoxify 6-MP, resulting in severe and possibly fatal myelosuppression [6] .
The findings in this study support the idea that a patient with (TA) 7 TAA {UGT1A1*28) allele has an impaired capacity for glucuronidation of SN-38 compared with the patients with wild type allele. The result, however, derived from only one patient with 7/7 genotype, and this preliminary report needs to be further corroborated. This work might be somewhat complicated by the succeeding carboplatin infusion, and a monotherapy would be suitable for this kind of study. However, we consider it unlikely that carboplatin would influence a metabolic pathway of irinotecan because carboplatin is excreted via kidney without being metabolized or conjugated in liver. We hypothesize that patients with 7/7 genotype would have an increasing hematological toxicity and/or diarrhea due to an excessive exposure to SN-38. In our recent study, we found two subjects with 7/7 genotype among 58 Japanese (about 3%). Therefore, we are planning to examine a relationship between these genotypes and toxicity of irinotecan in a large population. Should a relationship to a risk for severe toxicity of irinotecan be verified, perhaps irinotecan therapy could be individualized by gene diagnosis. In addition, we recently showed that the frequency of 7/7 genotype was significantly lower in Japanese than in Caucasians (incidence of 12%) [3, 4] . This finding suggests that not only inter-individual but also inter-ethnic differences exist in the metabolic profile of irinotecan.
Since the dose of irinotecan in this study was unanimously agrred to, it is possible that the patients with 6/6 genotype may have received an under-dose of the drug. When a genetic polymorphism exists in the enzyme involved in a metabolic pathway, a uniform dose carries the potential risk that the drug will be under-or overdosed for extensive or poor metabolizers, respectively. Wasserman et al. has reported the occurrence of severe toxic effects of irinotecan treatment in two patients with unconjugated hyperbilirubinemia [7] . They proposed that bilirubin level could be a predictive parameter of irinotecan toxicity and also be a tool for optimizing individual dosing. However, the level of bilirubin as an endogenous compound could be easily influenced by non-genetic factors, such as diet, therapeutic drug use or liver disease, masking the genetic effects. We propose that individualization of the dose of irinotecan by gene diagnosis would be better than phenotyping of UGT1A1 by determination of bilirubin.
